Escitalopram 10mg Tablet (Escitalopram Oxalate)

Adult administration

The safety of doses exceeding 20mg per day has not been established. This drug is administered once daily in the morning or evening, regardless of meals. Major depressive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. If the dose of this drug is to be increased to 20mg, it should be increased at intervals of at least 1 week. In general, 2-4 weeks are needed for antidepressant effects to appear. Even after symptoms have resolved, drug treatment for at least 6 months is needed to ensure a therapeutic effect. Panic disorder with or without agoraphobia: It is recommended to administer an initial dose of 5mg once daily for 1 week, then increase to 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. The maximum effect appears after approximately 3 months. The safety and efficacy of long-term administration of this drug for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reassess each patient to determine the need for continued treatment. Social anxiety disorder: The usual dose is 10mg once daily. In general, 2-4 weeks are needed for symptoms to improve. Thereafter, depending on the patient's response, the dose may be reduced to 5mg per day or increased to a maximum of 20mg per day. Social anxiety disorder is a condition with a chronic course, and continued treatment for 12 weeks is recommended to ensure a therapeutic effect. Long-term treatment in patients who respond has been studied for 6 months and should be considered individually for each patient to prevent relapse. The usefulness of long-term treatment should be reassessed regularly. Social anxiety disorder is a well-defined diagnostic term for a specific disorder and should not be confused with excessive shyness. Drug treatment should be used only when social anxiety disorder significantly interferes with occupational and social activities. Drug treatment has not been compared with cognitive behavioral therapy. Drug treatment is one part of an overall treatment strategy. Generalized anxiety disorder: The initial dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day after at least 1 week of treatment. A long-term study was conducted in patients who responded to 12 weeks of open-label treatment, in which 20mg per day was administered for at least 6 months. The physician should regularly reassess the usefulness of long-term treatment with this drug for each patient. Obsessive-compulsive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. A long-term study was conducted in patients who responded to 16 weeks of open-label treatment, in which 10mg or 20mg per day was administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition; treatment should be continued for a sufficient period to ensure recovery from symptoms. If this drug is used long term, the usefulness and dose should be regularly reassessed for each patient. No dose adjustment is necessary in patients with mild or moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30mL/min). An initial dose of 5mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased to 10mg per day. When discontinuing this drug, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this drug, an interval of at least 14 days must be allowed. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 14 days must have elapsed after discontinuation of this drug. Patients receiving linezolid or intravenous methylene blue must not start treatment with this drug because of the increased risk of serotonin syndrome. Treatment may be considered for patients who require other interventions, including hospitalization, or treatment for a more urgent psychiatric condition. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this drug. If there is no alternative to linezolid or intravenous methylene blue and, for a particular patient, the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome, this drug may be discontinued immediately and linezolid or intravenous methylene blue administered. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever comes first. Treatment with this drug may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with methylene blue administered by non-intravenous routes (oral tablets or local injection) or with intravenous administration of this drug at a dose of 1mg/kg or less is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is an antidepressant used for the treatment of psychiatric disorders such as major depressive disorder. During the course of treatment, there is an increased risk of suicidal thoughts or behaviors in children, adolescents, and young adults aged 18 to 24 years, so it should be used with great caution under a physician's supervision. This medication should not be administered to patients with hypersensitivity to it or those taking specific medications such as MAO inhibitors, pimozide, and drugs that prolong the QT interval. Patients with closed-angle glaucoma or a history of glaucoma should be cautious due to the risk of increased intraocular pressure from the mydriatic effect of this medication. Common side effects can occur during the first 1-2 weeks of treatment, including anxiety, insomnia, dizziness, and nausea, often improving over time. Especially, this medication can induce psychiatric side effects such as suicidal thoughts, aggression, and hallucinations, so patients and families should carefully observe symptoms. Additionally, this medication may lower sodium concentration in the blood, necessitating caution in elderly patients or those with liver disease or at risk for hyponatremia. Serious side effects known as serotonin syndrome can occur when used with other serotonergic drugs, so extra caution is needed when co-administering. Abrupt discontinuation of the drug can lead to withdrawal symptoms such as dizziness, anxiety, and sleep disturbances, therefore doses should be gradually reduced in consultation with a physician. Patients with heart disease or a prolonged QT interval should have their cardiac status checked by an ECG before and during treatment with this medication. Pregnant or nursing women should consult a physician before use, as this medication may affect the fetus or newborn. Elderly patients should start with a lower initial dose and closely monitor for side effects. Care should be taken when driving or operating machinery, so it is important to ascertain the effect of the medication on oneself after consumption. When storing this medication, keep it out of reach of children and avoid transferring it to another container for safety.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, loss of appetite, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, nervousness, panic attack, confusion, aggression, depersonalization, hallucination, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, dysesthesia, tremor, taste disorder, sleep disorder, syncope, serotonin syndrome, movement disorder, abnormal movements, seizures, psychomotor agitation, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, prolonged QT interval on ECG, polymorphic ventricular tachycardia, orthostatic hypotension, sinusitis, yawning, epistaxis, nausea, diarrhea, constipation, vomiting, thirst, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, petechiae, angioedema, joint pain, muscle pain, rhabdomyolysis, urinary retention, ejaculation disorder, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, priapism, fatigue, fever, edema, headache, paresthesia, paralysis, extrapyramidal disorder, migraine, cough, asthma, dyspnea, chest pain, fractures, palpitations, hypertension, insomnia, aggressive reaction, loss of appetite, drowsiness, sedation, dry mouth, abdominal pain, indigestion, enteritis, dysesthesia, increased urination, tremor, abdominal discomfort, anxiety, visual hallucinations, retroactive anxiety, epileptic seizure, mania, suicidal impulse, suicidal behavior, hostility, aggression, anger, akathisia, discomfort, anxiety, dizziness, sleep disorder, confusion, sweating, diarrhea, emotional instability, irritability, visual impairment, withdrawal symptoms, hypokalemia, hypomagnesemia, QT interval prolongation, sexual dysfunction, persistent sexual dysfunction

This medication is sensitive to light and should be stored in a container that does not allow light. It is also advisable to store it at room temperature between 1°C and 30°C. Proper storage helps maintain the efficacy of the drug.

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle